Merck & Co., Inc: Hypercholesterolemia trials

The registry lists 29 Hypercholesterolemia studies with Merck & Co., Inc as lead sponsor. 1 are open to participants now and 16 have results posted.

Phase 1 6Phase 2 4Phase 3 17No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)RecruitingNCT07821944Phase 3
• A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)CompletedNCT06450366Phase 3Results posted
• A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)CompletedNCT05952869Phase 3Results posted
• A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef LipidsCompletedNCT05952856Phase 3Results posted
• Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)CompletedNCT05934292Phase 1Results posted
• A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)CompletedNCT05261126Phase 2Results posted
• Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)TerminatedNCT01335997Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)TerminatedNCT01294683Phase 3Results posted
• Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)TerminatedNCT01274559Phase 3Results posted
• Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204)CompletedNCT01245738Results posted
• Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)TerminatedNCT01228019Results posted
• Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED)CompletedNCT00935259Phase 1Results posted
• A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)CompletedNCT00769132Phase 1Results posted
• A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)CompletedNCT00687271Phase 2Results posted
• Effect of MK0524A on Cholesterol Levels (0524A-048)CompletedNCT00536510Phase 3Results posted
• MK-0524B Lipid Study (MK-0524B-063)CompletedNCT00479882Phase 3Results posted
• Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)CompletedNCT00479388Phase 3Results posted
• A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)CompletedNCT06655311Phase 1
• A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)CompletedNCT06592339Phase 1
• Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef ExtensionActive, not recruitingNCT06492291Phase 3
• Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef OutcomesActive, not recruitingNCT06008756Phase 3
• A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)CompletedNCT01860729Phase 3
• A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)CompletedNCT01717300Phase 3
• A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)CompletedNCT00565292Phase 1
• MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)CompletedNCT00533312Phase 2
• Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)CompletedNCT00378833Phase 3
• Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)CompletedNCT00376584Phase 3
• MK0859 Dose-Ranging Study (0859-003)TerminatedNCT00325455Phase 2
• A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)(COMPLETED)CompletedNCT00092846Phase 3